Latrodectus antivenin

Drug Profile

Latrodectus antivenin

Alternative Names: Analatro; Antivenin Latrodectus equine immune F(ab)2 - RDT/Bioclon; Aracmyn; Black widow spider antivenin - RDT/Bioclon; Black widow spider antivenom - RDT/Bioclon; Latrodectus immune F(ab’)2 antivenom - Instituto Bioclon/Rare disease therapeutics; Spider venom antiserum - RDT/Bioclon

Latest Information Update: 21 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Instituto Bioclon
  • Developer Instituto Bioclon; Rare Disease Therapeutics
  • Class Antibodies; Antivenins
  • Mechanism of Action Spider venom inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spider venom poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Spider venom poisoning

Most Recent Events

  • 12 Aug 2005 Phase-II clinical trials in Spider venom poisoning in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top